mHAM based drug for Osteoarthritis
symptoms treatment

mHAM orthopedics 1102 injectable

Mechanism of action

Based on our more then 10 years research of placenta tissue, we developed human amniotic membrane platform (HAM platform), with patented technology AmniPur®. New drug candidate is based on our invention how to protect wide range of bioactive molecules like grow factors and cytokines in their original structure, supporting cells diferenciation in affected region and so cause:


The aim is clinical developement of the Novel Osteoarthrosis Symptoms Drug, which significantly and immediatelly decrease a pain in joints affected area, simultaneously replaicing opioids, improve of join mobility and decrease of inflammation.

Medical Problem

16% of Europe population suffere of Osteoarthritis. Two and half millions of them get TEP replacement / year with a cost of EUR 85B+ a year. In the past 5 years, the number of surgical operations in the endoprosthesis has increased by 80%. Rejection reaction or manifestation of hypersensitivity to the implant material is observed in 6 – 30% of cases of surgical intervention. Immune reaction is one of the causes of complications of bone tissue on implants.

USA is the number one consumer of narcotic drugs, with 40 240 defined daily dosages of opioids per million inhabitants per day. In second place is Germany with 28 862 defined daily dosages per 1 million inhabitants, followed by Canada with 26 029. The Netherlands is in ninth place, with 16 114 defined daily dosages per 1 million inhabitants.
Source: Data from the 2018 report by the International Narcotics Control Board,